Medicare Enrolled
Dr. Ayham Al Ashkar, MD
Medical Oncology · Royal Oak, MI
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Al Ashkar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Al Ashkar?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Al Ashkar
Dr. Ayham Al Ashkar is a medical oncology specialist in Royal Oak, MI, with 19 years of NPI registration. Based on federal Medicare data, Dr. Al Ashkar performed 97,662 Medicare services across 2,481 unique beneficiaries.
Between the years covered by Open Payments, Dr. Al Ashkar received a total of $2,032 from 33 pharmaceutical and/or device companies across 98 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Al Ashkar is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 7% volume in MI
$2,032 industry payments
Medicare Practice Summary
Medicare Utilization ↗97,662
Medicare services
Top 7% in MI for medical oncology
2,481
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~5,140 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
33,000 | $1 | $4 |
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
31,110 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 8,200 | $43 | $165 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
5,250 | $0 | $1 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
4,320 | $6 | $24 |
| Denosumab injection (Prolia/Xgeva) | 4,140 | $18 | $72 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
2,290 | $23 | $89 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,850 | $0 | $1 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
873 | $8 | $20 |
| Anti-nausea injection (Aloxi/palonosetron) | 800 | $1 | $4 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
618 | $69 | $265 |
| Basic blood chemical test (calcium, ionized) A blood test that measures basic chemical levels, specifically including calcium and ionized calcium. |
583 | $13 | $41 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
370 | $64 | $206 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
363 | $23 | $96 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
312 | $71 | $273 |
| Injection, granisetron hydrochloride, 100 mcg | 310 | $0 | $2 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
306 | $104 | $443 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
286 | $11 | $42 |
| Pegfilgrastim-jmdb injection An injection of pegfilgrastim-jmdb, a biosimilar medication. The dose specified is 0.5 mg. |
264 | $98 | $379 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 255 | $3 | $11 |
| Anti-nausea injection (ondansetron/Zofran) | 228 | $0 | $1 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
200 | $40 | $113 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
178 | $6 | $27 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
173 | $49 | $221 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
159 | $12 | $51 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
157 | $2 | $8 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
128 | $99 | $376 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
125 | $140 | $576 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
110 | $23 | $94 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
102 | $1 | $4 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
99 | $51 | $214 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
84 | $58 | $247 |
| New patient office visit, complex (60-74 min) | 74 | $172 | $648 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
68 | $95 | $294 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
38 | $44 | $185 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
37 | $103 | $392 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
37 | $1 | $6 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
28 | $67 | $328 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
27 | $15 | $59 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
23 | $135 | $491 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
23 | $2 | $8 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
19 | $26 | $107 |
| Hospital discharge day management, 30 minutes or less This service covers the final day of hospital care when the patient is being discharged. It includes coordination of care and instructions for the patient within a time frame of 30 minutes or less. |
19 | $65 | $208 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
14 | $30 | $123 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
12 | $144 | $528 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
66.7% high complexity
30.1% medium
3.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,032
Total received (2018-2024)
Avg $290/year across 7 years
Bottom 47% in MI for medical oncology
33
Companies
98
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,806 (88.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$225 (11.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$16
2023
$612
2022
$813
2021
$95
2020
$49
2019
$386
2018
$60
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Mirati Therapeutics, Inc.
$16
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
PFIZER INC.
$216
AVEO Pharmaceuticals, Inc.
$198
Amgen Inc.
$179
Genentech USA, Inc.
$175
Janssen Biotech, Inc.
$136
GlaxoSmithKline, LLC.
$122
AstraZeneca Pharmaceuticals LP
$104
Merck Sharp & Dohme Corporation
$98
Mirati Therapeutics, Inc.
$85
Seagen Inc.
$80
GENZYME CORPORATION
$61
E.R. Squibb & Sons, L.L.C.
$55
Novartis Pharmaceuticals Corporation
$51
Celgene Corporation
$47
Gilead Sciences, Inc.
$44
Daiichi Sankyo Inc.
$38
Ipsen Biopharmaceuticals, Inc
$38
Pharmacyclics LLC, An AbbVie Company
$38
TESARO, Inc.
$29
Kite Pharma, Inc.
$27
Astellas Pharma US Inc
$27
TAIHO ONCOLOGY, INC.
$26
Rigel Pharmaceuticals, Inc.
$19
MorphoSys, US Inc.
$19
Stemline Therapeutics Inc.
$17
Dendreon Pharmaceuticals LLC
$16
BeiGene USA, Inc.
$16
Lilly USA, LLC
$16
G1 Therapeutics, Inc.
$13
Aveo Pharmaceuticals, Inc.
$12
Fortovia Therapeutics, Inc.
$12
Epizyme, Inc.,
$12
Penumbra, Inc.
$6
Top 3 companies account for 29.2% of all-time payments
Associated products mentioned in payments ›
ALIMTA · BAVENCIO · BRUKINSA · Balversa · Blincyto · CALQUENCE · COSELA · DARZALEX · FOTIVDA · GAZYVA · Herceptin · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · Indigo System · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LONSURF · LUMAKRAS · MONJUVI · Nplate · OPDIVO · OPDUALAG · Orserdu · PADCEV · PROMACTA · PROVENGE · Pomalyst · REBLOZYL · Rezlidhia · SOMATULINE DEPOT · SUTENT · Somatuline Depot · TAGRISSO · TAZVERIK · TECENTRIQ · TUKYSA · Trodelvy · Venclexta · XTANDI · Xospata · Xtandi · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (89%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
33
Per 100K population
2.6
County median income
$95,296
Nearest hospital
BEAUMONT HOSPITAL ROYAL OAK
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Al Ashkar is a mixed practice specialist, with above-average Medicare volume (top 7% in MI), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Al Ashkar experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Al Ashkar performed 33,000 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Al Ashkar receive payments from pharmaceutical companies?
Yes. Dr. Al Ashkar received a total of $2,032 from 33 companies across 98 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Al Ashkar's costs compare to other medical oncologists in Royal Oak?
Dr. Al Ashkar's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Al Ashkar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Royal Oak
Browse medical oncologists in Royal Oak ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in MI
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in MI
Which MI medical oncologists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
AVEO Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from AVEO Pharmaceuticals, Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology